FIG. 1.

Disabling Nmp4 enhanced PTH-induced increases in femoral cancellous bone after 3 weeks of treatment. Microcomputed tomography-acquired femoral trabecular architecture, including (A) BV/TV%; (B) Conn D mm⁻³; (C) SMI; (D) Tb.Th mm: (E) Tb.N mm⁻¹: (F) Tb.Sp mm was compared between WT and Nmp4-KO mice that had been treated with intermittent hPTH (1–34) 30 μg/kg/day or vehicle for 3 weeks (average±SD, number of mice/experimental group=10). Statistical differences were determined using a 2-way ANOVA. A Tukey's HSD post hoc test was used to determine differences between the treatment groups if a significant genotype×treatment interaction was indicated, and there was such an interaction for BV/TV, Conn D, SMI, and Tb.Th. HSD, honestly significant difference; PTH, parathyroid hormone; VEH, vehicle; SMI, structure model index; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular spacing; WT, wild type; KO, knockout.